Cholesterol Pharmacology Plaque 
JAMA Cardiology
SEPTEMBER 1, 2024
After the introduction of statins in 1987 and the publication of the landmark Scandinavian Simvastatin Survival Trial in 1996, extraordinarily robust evidence has accumulated demonstrating that lowering levels of low-density lipoprotein cholesterol (LDL-C) is associated with a major reduction in cardiovascular morbidity and mortality.
Frontiers in Cardiovascular Medicine
MARCH 4, 2024
The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors. For cardiovascular disease, only low-density lipoprotein cholesterol and blood pressure are approved as surrogates for cardiovascular disease.
DAIC
APRIL 11, 2024
These new findings suggest that people with high-risk plaques that are likely to rupture could benefit from the procedure as a pre-emptive measure rather than waiting for a heart attack or other severe reduction in blood flow to occur. During PCI, an operator inserts a stent into a blocked artery through a catheter in the groin or arm.
DAIC
JANUARY 23, 2024
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 7 Research has shown inflammation plays a significant role in the development of atherosclerosis and ASCVD,8-10 and even the formation of plaque.11 4 In the U.S. N Engl J Med.
DAIC
MAY 16, 2024
PAD is a serious, progressive cardiovascular disease primarily caused by a buildup of fatty plaque in the blood vessels, or atherosclerosis. This plaque narrows the blood vessels and reduces blood flow to the legs and feet, which may significantly impair physical function, walking performance and quality of life.
Expert insights. Personalized for you.
70 
Let's personalize your content